Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis

doi:10.1097/CAD.0b013e32833304c5

CORC > 兰州大学 > 兰州大学 > 基础医学院 > 期刊论文

	Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis
	Liu, RF; Wang, XH; Ma, B; Yang, KH; Zhang, QN; Tian, JH; Wang, XH (reprint author), Tumor Hosp Gansu Prov, Radiol Oncol Ctr, Lanzhou 730050, Peoples R China.
刊名	ANTI-CANCER DRUGS
	2010-01
卷号	21 期号:1 页码:120-128
关键词	brain metastases systematic review temozolomide whole-brain irradiation
ISSN号	0959-4973
DOI	10.1097/CAD.0b013e32833304c5
文献子类	Article
英文摘要	The objective of this study was to assess the clinical efficacy and safety of concomitant or adjuvant tomozolomide with whole-brain irradiation (WBI) in patients with brain metastases. MEDLINE, EMBASE, Cochrane Library, Chinese Biomedical Literature Database were searched to identify relevant original published trails, and the references of eligible studies were manually screened. Randomized controlled trails reported in any language, comparing concomitant or adjuvant temozolomide (TMZ) and WBI with WBI alone in patients with brain metastases, were eligible for inclusion. Two investigators independently assessed the quality of included trials and extracted data. The RevMan 5 software was used for statistical analysis. Four trials involving 280 patients were included. The result showed that the group TMZ + WBI was superior to group WBI in partial response, stable disease, progressive disease, and objective response with the pooled risk ratio value and 95% confidence interval, respectively, 1.89 (1.19-3.02), 0.82 (0.45-1.50), 0.29 (0.10-0.78), and 1.72 (1.32-2.24). The incidence of gastrointestinal symptoms and >= grade 3 myelosuppression presented statistical difference, TMZ+WBI group is higher than WBI group, the pooled risk ratio value and 95% confidence interval were 3.75 (1.04-13.44) and 13 (1.75-96.79), respectively. The currently available evidence showed that the combination of TMZ and WBI may moderately improve the response rate, but accordingly increase the incidence of gastrointestinal symptoms and myelosuppression. Future large-scale, high-quality, placebo-controlled, double-blind trials are needed. Anti-Cancer Drugs 21:120-128 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
学科主题	Oncology ; Pharmacology & Pharmacy
出版地	PHILADELPHIA
语种	英语
WOS记录号	WOS:000273021800014
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/121430]
专题	基础医学院_期刊论文
通讯作者	Wang, XH (reprint author), Tumor Hosp Gansu Prov, Radiol Oncol Ctr, Lanzhou 730050, Peoples R China.
推荐引用方式 GB/T 7714	Liu, RF,Wang, XH,Ma, B,et al. Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis[J]. ANTI-CANCER DRUGS,2010,21(1):120-128.
APA	Liu, RF.,Wang, XH.,Ma, B.,Yang, KH.,Zhang, QN.,...&Wang, XH .(2010).Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis.ANTI-CANCER DRUGS,21(1),120-128.
MLA	Liu, RF,et al."Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis".ANTI-CANCER DRUGS 21.1(2010):120-128.